PMID- 12901342
OWN - NLM
STAT- MEDLINE
DCOM- 20031015
LR  - 20160422
IS  - 1540-3408 (Print)
IS  - 1540-3408 (Linking)
VI  - 2
IP  - 3
DP  - 2003 May
TI  - Hemopoietic cell transplantation for myelodysplastic syndromes.
PG  - 209-16
AB  - Myelodysplastic syndromes are clonal stem cell disorders, and allogeneic 
      hemopoietic cell transplantation (HCT) is the only therapy with curative 
      potential. Among patients with less-advanced myelodysplastic syndromes, 3-year 
      survivals of 65% to 75% are achievable with human leukocyte antigen 
      (HLA)-identical related and HLA-matched unrelated donors. The probability of 
      relapse is less than 5%. Among patients with advanced disease (> or = 5% marrow 
      blasts), 35% to 45% and 25% to 30%, respectively, are surviving in remission 
      after transplantation from related or unrelated donors. The incidence of 
      post-transplant relapse is 10% to 35%. Criteria of the International Prognostic 
      Scoring System, originally developed for nontransplanted patients, also predict 
      relapse and survival after HCT. Refined conditioning regimens have permitted 
      successful HCT even in patients in their seventh decade of life. Results with a 
      regimen using a combination of busulfan (targeted to predetermined plasma levels) 
      and cyclophosphamide are particularly encouraging. Improved survival with 
      transplants from unrelated volunteer donors reflects selection of donors on the 
      basis of high-resolution (allele-level) HLA typing. Nevertheless, 
      transplant-related morbidity and mortality, including graft-versus-host disease, 
      remain challenges that need to be addressed with innovative approaches. Some 
      patients who achieve a chemotherapy-induced complete remission may also benefit 
      from autologous HCT.
FAU - Benesch, Martin
AU  - Benesch M
AD  - Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, PO 
      Box 19024, Seattle, WA 98109, USA.
FAU - Deeg, H Joachim
AU  - Deeg HJ
LA  - eng
GR  - CA18029/CA/NCI NIH HHS/United States
GR  - CA87948/CA/NCI NIH HHS/United States
GR  - HL36444/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Curr Hematol Rep
JT  - Current hematology reports
JID - 101151358
SB  - IM
MH  - Age Factors
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Myelodysplastic Syndromes/*therapy
MH  - Neoplasms, Second Primary/etiology/therapy
MH  - Treatment Outcome
RF  - 54
EDAT- 2003/08/07 05:00
MHDA- 2003/10/16 05:00
CRDT- 2003/08/07 05:00
PHST- 2003/08/07 05:00 [pubmed]
PHST- 2003/10/16 05:00 [medline]
PHST- 2003/08/07 05:00 [entrez]
PST - ppublish
SO  - Curr Hematol Rep. 2003 May;2(3):209-16.